Medis receives two nominations for this year’s Global Generics & Biosimilar Awards; as Company of the Year, and Company of the Year, EMEA.
The shortlist for the 14 prestigious 2017 awards was published recently in a special edition of Generics Bulletin, featuring Medis with nominations for two awards, and Teva, Medis’ parent company, receiving nominations in three categories; Patent Litigation of the Year, Business Development of the Year and Biosimilar Initiative of the Year.
The winners in each category will be announced at a ceremony in Frankfurt on October 24, when most of the generic pharmaceutical industry will be gathered there for the CPhI Worldwide conference at Messe Frankfurt that week.
A panel of expert judges assessed around 100 nominations for the awards to create the shortlist of four finalists for each award. Medis has regularly featured as a finalist, and on one occasion the company took home the award for Business Development of the year, in 2015, for successfully being the first, or among the first, to launch Pregabalin in several markets with its customers.
About the Global Generics & Biosimilar Awards
The Global Generics & Biosimilars Awards reward ‘best practice’ in the two industries, while at the same time encouraging improvements in every aspect of the way business is conducted.
Business development initiatives – such as through innovative product development, clever licensing deals or smart legal maneuvers – are at the heart of the Global Generics & Biosimilars Awards. Equally important will be recognizing the industries’ best executives and leading companies.
Every Award will effectively underscore the efforts made by the global generics and biosimilars industries to make more affordable medicines available to more people everywhere.
The Awards will be presented for the fourth time on 24 October 2017 in Frankfurt, Germany.